The authors conclude that there is a favourable risk/benefit profile, justifying the cautious use of antidepressants as a first-line treatment option. It is likely, however, that they have underestimated the risk of suicidal behaviour. Youths at risk were excluded from the trials and data were only collected retrospectively as part of adverse event reporting.